James A Schoeneck insider trades: Calidi Biotherapeutics (CLDI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | CLDI | ↑ Buy | 75,000 | $2.00 | $150K | Direct | Aug 25, 2025 (4d) |
| Jun 30, 2025 | FGEN | ↑ Buy | 23,567 | $5.07 | $119K | By Trust | Jul 2, 2025 (2d) |
| Mar 21, 2025 | FGEN | ↑ Buy | 300,000 | $0.35 | $105K | By Trust | Mar 24, 2025 (3d) |
| Jun 7, 2023 | FGEN | ↓ Sell | 7,100 | $18.03 | $128K | By Trust | Jun 9, 2023 (2d) |
| May 7, 2019 | FGEN | ↓ Sell10b5-1 | 2,000 | $47.02 | $94K | Direct | May 9, 2019 (2d) |
| Apr 8, 2019 | FGEN | ↓ Sell10b5-1 | 2,000 | $52.90 | $106K | Direct | Apr 10, 2019 (2d) |
| Mar 7, 2019 | FGEN | ↓ Sell10b5-1 | 2,000 | $54.74 | $109K | Direct | Mar 8, 2019 (1d) |
| Feb 7, 2019 | FGEN | ↓ Sell10b5-1 | 2,000 | $57.17 | $114K | Direct | Feb 8, 2019 (1d) |
| Jan 7, 2019 | FGEN | ↓ Sell10b5-1 | 2,000 | $45.90 | $92K | Direct | Jan 9, 2019 (2d) |
| Jul 3, 2018 | FGEN | ↓ Sell10b5-1 | 7,639 | $65.00 | $497K | Direct | Jul 6, 2018 (3d) |
| Jun 22, 2018 | FGEN | ↓ Sell10b5-1 | 4,361 | $65.00 | $283K | Direct | Jun 26, 2018 (4d) |
| Dec 2, 2014 | DEPO | ↓ Sell10b5-1 | 36,727 | $15.85 | $582K | Direct | Dec 3, 2014 (1d) |
| Mar 14, 2014 | DEPO | ↓ Sell | 17,000 | $14.54 | $247K | By Trust | Mar 14, 2014 (0d) |
| Dec 2, 2013 | DEPO | ↓ Sell10b5-1 | 17,192 | $8.40 | $144K | Direct | Dec 4, 2013 (2d) |
| May 10, 2013 | DEPO | ↑ Buy | 25,000 | $5.11 | $128K | Direct | May 13, 2013 (3d) |
| Aug 23, 2011 | DEPO | ↑ Buy | 20,000 | $5.13 | $103K | Direct | Aug 24, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CLDI insiders
Open-market trades in the last 12 months
About James A Schoeneck's insider trades
James A Schoeneck is a director at Calidi Biotherapeutics (CLDI). Since Aug 23, 2011, James has reported 5 open-market purchases worth $605K and 11 sales worth $2.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
9 sales (84% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (36 filings), option exercises (20 filings), gifts (12 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CLDI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.